Stockreport

Axsome Therapeutics Announces Positive Outcome of Interim Analysis of ADVANCE-1 Phase 2/3 Trial of AXS-05 in Alzheimer’s Disease Agitation

Axsome Therapeutics, Inc.  (AXSM) 
Last axsome therapeutics, inc. earnings: 3/12 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: axsome.com
PDF IDMC recommends continuation of trial evaluating AXS-05 versus placebo in Alzheimer’s disease agitation IDMC recommends no further enrollment to single-agent bupropion [Read more]